Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

Elena Fountzilas(European University Cyprus), G. Koumakis(St Savas Hospital), Ioannis Boukovinas, Zacharenia Saridaki(Clinic Asklepio Larissa), Efthalia Lalla(Theageneio General Hospital), Davide Mauri(University Hospital of Ioannina), Adamantia Nikolaidi(Mitera Hospital), Cleopatra Rapti(Hellenic Airforce General Hospital), Ioannis Kontogiorgos(University of Piraeus), Sofia Karageorgopoulou(National and Kapodistrian University of Athens), Anastasios Boutis(Theageneio General Hospital), Eleni Res(Hospital Agioi Anargyroi), Dimitrios Tryfonopoulos(St Savas Hospital), Georgia-Angeliki Koliou(Hellenic Cooperative Oncology Group), Sofia Karteri(University of Patras), Gerasimos Aravantinos(Hospital Agioi Anargyroi), George Fountzilas(Aristotle University of Thessaloniki), Giannis Mountzios(Henry Dunant Hospital), Flora Zagouri(National and Kapodistrian University of Athens), Amanda Psyrri(University General Hospital Attikon), Athina Christopoulou(Agios Andreas Hospital), Achilleas Nikolakopoulos(University of Patras), Ioannis Binas(Metropolitan Hospital), Anna Koumarianou(National and Kapodistrian University of Athens), Vassiliki Rapti(St Savas Hospital), Evangelia Razis(Hygeia Hospital), Dimitrios Bafaloukos(Metropolitan Hospital), Helena Linardou(Metropolitan Hospital), Evangelia Moirogiorgou(Hygeia Hospital), Athanassios Vozikis(University of Piraeus)

ESMO Open

January 1, 2020

Cited by 38

|New England Journal of Medicine|2022|2.5k

|Cancer Treatment Reviews|2020|747

|Journal of Clinical Oncology|2010|488

|Genome Medicine|2022|279

|Cancer Research|2011|266

Related Papers